Clinical trial NCT00035178: Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
Official title: Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Failure, Chronic
Renal Disease, End-Stage
Keywords: ESRD
End-stage renal disease
Hemodialysis
Lead sponsor: Encysive Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2002-05-03
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.


Eligibility criteria: Basic Inclusion Criteria:

1. Patients, adult men or women who are between 21 and 75 years of age who are on maintenance hemodialysis regimen for at least three (3) months prior to the study start.
2. Patients who can tolerate a hemodialysis session lasting up to 9 hours.
3. Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per minute.
4. Female volunteers who are not documented to be surgically sterile must be willing to abstain from sexual intercourse during the study or be willing to use intrauterine devices or 2 forms of barrier contraception for at least 7 days prior to the initial dose of study medication and continuing through the completion of the study.

Basic Exclusion Criteria:

1. Any clinically relevant abnormality identified per the investigator on the screening medical assessment or laboratory examination.
2. History of regular alcohol abuse.
3. Treatment with an investigational drug within 30 days.
4. History of drug allergy of clinical significance in the opinion of the investigator.
5. Currently taking warfarin or other anticoagulants.
6. Currently taking NSAIDs (with the exception of aspirin).
7. Individuals who are obese.
8. Any history of bleeding disorder.
9. Any subject with a screening resting systolic blood pressure \>180 mmHg and/or resting diastolic blood pressure of \>100 mmHg unless, in the opinion of the principal investigator, the blood pressures would not endanger the subject while participating in this trial.
10. Concurrent uncontrolled cardiovascular, hematologic, respiratory, CNS, gastrointestinal disease or chronic alcoholism.
11. Anemia defined as a hematocrit of \< 30 and hemoglobin \< 10g/dL.
12. Concurrently taking (within the past 30 days) phenytoin, cimetidine, rifampin, cyclosporin or tacrolimus.
13. Known hypersensitivity to Argatroban or related compounds.
14. Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago, Section of Nephrology
state: Illinois
city: Minneapolis
country: United States
facility: DaVita Clinical Research
state: Minnesota
Study officials:
References: